Stocks were weak in early trading this morning with all major benchmarks 1% or less from their record highs. A move lower in bond yields squashed enthusiasm for cyclical stocks that are closely linked to a recovering economy.
Market gains will come and go, but chronic conditions – by definition – don’t take a break. Today’s trade alert highlights a biotech company focused on treating chronic conditions. Considering the enormous commercial potential, the stock may be severely undervalued.
BiomX Inc. (PHGE) is a clinical-stage microbiome company using its novel BOLT phage therapy platform to develop customized phage therapies to treat chronic diseases ranging from IBC, colorectal cancer, Cystic Fibrosis and acne. Currently there are 6 programs in the pipeline. Early pre-clinical and clinical results have been promising.
The Israeli biotech is company utilizing proprietary next-generation synthetic biology platforms and technologies, (including its high-resolution DNA analysis, AI, cloud computing and other computational tools) to develop phage cocktails (both naturally occurring and engineered) as a novel mode of action to treat various chronic and other diseases, including those that have become resistant to current antibiotics.
Shareholders include Orbimed, Takeda and Johnson & Johnson. BiomX has also entered into collaboration agreements with Janssen, Boehringer Ingelheim, and others.
BiomX‘s market cap is approximately $133 million with nearly $50 million in cash or equivalents (as of March 2021).
While BiomX is in early stage, its phage therapy technology looks very promising and if proven out, BiomX could generate substantial upside for investors. The four analysts who offer recommendations for PHGE all rate the stock a Buy. A median 12-month price target of $22.50 represents a 309% upside.
Where to invest $1,000 right now...
Before you consider buying BiomX, you'll want to see this.
Investing legend, Keith Kohl just revealed his #1 stock for 2022...
And it's not BiomX.
Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on this tiny company that trades publicly for $5.
Keith say’s he thinks investors will be able to turn a small $50 stake into $150,000.
Find that to be extraordinary?
Click here to watch his presentation, and decide for yourself...
But you have to act now, because a catalyst coming in a few weeks is set to take this company mainstream... And by then, it could be too late.
Click here to find out the name and ticker of Keith's #1 pick...
